The Therapeutic Vaccine: Is it Feasible?

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 493-498

  Gissmann, Lutz ^a   Nieto, Karen ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cervical cancer; HPV infections; HPV vaccines; Immune mechanism controlling HPV infections; Therapeutic vaccine

Indexed keywords

ADJUVANT; CALRETICULIN; HPV16 E7 35MER PEPTIDE; HPV16 L2 E6 E7 FUSION PROTEIN; HSP 65 E7 VACCINE; HYBRID PROTEIN; LIPOPROTEIN; LIPOPROTEIN D VACCINE; PEPTIDE VACCINE; PLACEBO; PROTEIN E7; UNCLASSIFIED DRUG; VACCINIA VECTOR; VIRUS VACCINE; VIRUS VECTOR; WART VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CELL GROWTH; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; NONHUMAN; REVIEW; RODENT; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 70350077522     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.07.003     Document Type: Review

References (73)

1. Schneider A., Papendick U., Gissmann L., et al. Interferon treatment of human genital papillomavirus infection: importance of viral type. Int J Cancer 40 (1987) 610-614
2. Hasan U.A., Bates E., Takeshita F., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178 (2007) 3186-3197
3. Koromilas A.E., Li S., and Matlashewski G. Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 12 (2001) 157-170
4. Fausch S.C., Da Silva D.M., Rudolf M.P., et al. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 169 (2002) 3242-3249
5. Matthews K., Leong C.M., Baxter L., et al. Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin. J Virol 77 (2003) 8378-8385
6. Gruener M., Bravo I.G., Momburg F., et al. The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells. Virol J 4 (2007) 116
7. Strickler H.D., Burk R.D., Fazzari M., et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 97 (2005) 577-586
8. Konya J., and Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 82 (2001) 205-238
9. Scott M., Nakagawa M., and Moscicki A.B. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8 (2001) 209-220
10. Stern P.L., Brown M., Stacey S.N., et al. Natural HPV immunity and vaccination strategies. J Clin Virol 19 (2000) 57-66
11. Aiba S., Rokugo M., and Tagami H. Immunohistologic analysis of the phenomenon of spontaneous regression of numerous flat warts. Cancer 58 (1986) 1246-1251
12. Coleman N., Birley H.D., Renton A.M., et al. Immunological events in regressing genital warts. Am J Clin Pathol 102 (1994) 768-774
13. Arany I., Muldrow M., and Tyring S.K. Correlation between mRNA levels of IL-6 and TNF alpha and progression rate in anal squamous epithelial lesions from HIV-positive men. Anticancer Res 21 (2001) 425-428
14. Arany I., Tyring S.K., Stanley M.A., et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 43 (1999) 55-63
15. Hemmi H., Kaisho T., Takeuchi O., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
16. Galloway D.A. Serological assays for the detection of HPV antibodies. In: Munoz N., Bosch F.X., Shah K.V., and Meheus A. (Eds). The Epidemiology of Human Papillomavirus and Cervical Cancer (1992), IARC Scientific Publications, Lyon 147-161
17. Jochmus-Kudielka I., Schneider A., Braun R., et al. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst 81 (1989) 1698-1704
18. Meschede W., Zumbach K., Braspenning J., et al. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 36 (1998) 475-480
19. Campo M.S., Grindlay G.J., O'Neil B.W., et al. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J Gen Virol 74 Pt 6 (1993) 945-953
20. Jarrett W.F., Smith K.T., O'Neil B.W., et al. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology 184 (1991) 33-42
21. Zhang L.F., Zhou J., Chen S., et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 18 (2000) 1051-1058
22. Borysiewicz L.K., Fiander A., Nimako M., et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347 (1996) 1523-1527
23. Feltkamp M.C., Smits H.L., Vierboom M.P., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 (1993) 2242-2249
24. Munger K., Baldwin A., Edwards K.M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78 (2004) 11451-11460
25. Gissmann L. Human papillomaviruses. In: Bloom B.R., and Lambert P.H. (Eds). The Vaccine Book (2003), Academic Press, Amsterdam 311-322
26. Berry J.M., and Palefsky J.M. A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 8 (2003) s333-s345
27. Eiben G.L., da Silva D.M., Fausch S.C., et al. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16 (2003) 111-121
28. Arany I., Rady P., and Tyring S.K. Effect of interferon therapy on human papillomavirus copy number in patients with condyloma acuminatum. Am J Med Sci 310 (1995) 14-18
29. Rambout L., Hopkins L., Hutton B., et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177 (2007) 469-479
30. Hildesheim A., Herrero R., Wacholder S., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
31. Hafner N., Driesch C., Gajda M., et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 27 (2008) 1610-1617
32. DeFilippis R.A., Goodwin E.C., Wu L., et al. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 77 (2003) 1551-1563
33. Butz K., Ristriani T., Hengstermann A., et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22 (2003) 5938-5945
34. Gissmann L. Human papillomavirus vaccines. In: Meisels A., and Morin C. (Eds). Modern Uterine Cytopathology (2007), ASCP Press, Chicago 169-200
35. Kanodia S., Da Silva D.M., and Kast W.M. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int J Cancer 122 (2008) 247-259
36. Daemen T., Pries F., Bungener L., et al. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther 7 (2000) 1859-1866
37. Kaufmann A.M., Stern P.L., Rankin E.M., et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8 (2002) 3676-3685
38. Hopfl R., Sandbichler M., Sepp N., et al. Skin test for HPV type 16 proteins in cervical intraepithelial neoplasia. Lancet 337 (1991) 373-374
39. Hariharan K., Braslawsky G., Barnett R.S., et al. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int J Oncol 12 (1998) 1229-1235
40. Kim T.Y., Myoung H.J., Kim J.H., et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 62 (2002) 7234-7240
41. Adams M., Borysiewicz L., Fiander A., et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19 (2001) 2549-2556
42. Hallez S., Simon P., Maudoux F., et al. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 53 (2004) 642-650
43. Hsieh C.J., Kim T.W., Hung C.F., et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22 (2004) 3993-4001
44. Goldstone S.E., Palefsky J.M., Winnett M.T., et al. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45 (2002) 502-507
45. Kaufmann A.M., Nieland J.D., Jochmus I., et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121 (2007) 2794-2800
46. Greenstone H.L., Nieland J.D., de Visser K.E., et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95 (1998) 1800-1805
47. Buck C.B., Cheng N., Thompson C.D., et al. Arrangement of L2 within the papillomavirus capsid. J Virol 82 (2008) 5190-5197
48. Schäfer K., Müller M., Faath S., et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 81 (1999) 881-888
49. de Jong A., O'Neill T., Khan A.Y., et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20 (2002) 3456-3464
50. Brinkman J.A., Fausch S.C., Weber J.S., et al. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 4 (2004) 181-198
51. Muderspach L., Wilczynski S., Roman L., et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6 (2000) 3406-3416
52. Steller M.A., Gurski K.J., Murakami M., et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4 (1998) 2103-2109
53. van Driel W.J., Ressing M.E., Kenter G.G., et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 35 (1999) 946-952
54. Salit R.B., Kast W.M., and Velders M.P. Ins and outs of clinical trials with peptide-based vaccines. Front Biosci 7 (2002) e204-e213
55. Zwaveling S., Ferreira Mota S.C., Nouta J., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169 (2002) 350-358
56. Kenter G.G., Welters M.J., Valentijn A.R., et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14 (2008) 169-177
57. Klencke B., Matijevic M., Urban R.G., et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8 (2002) 1028-1037
58. Hedley M.L., Curley J., and Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4 (1998) 365-368
59. Meneguzzi G., Cerni C., Kieny M.P., et al. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 181 (1991) 62-69
60. Davidson E.J., Boswell C.M., Sehr P., et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 63 (2003) 6032-6041
61. Baldwin P.J., van der Burg S.H., Boswell C.M., et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9 (2003) 5205-5213
62. Corona Gutierrez C.M., Tinoco A., Navarro T., et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15 (2004) 421-431
63. Smyth L.J., Van Poelgeest M.I., Davidson E.J., et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 10 (2004) 2954-2961
64. Acres B., and Bonnefoy J.Y. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 7 (2008) 889-893
65. Cassetti M.C., McElhiney S.P., Shahabi V., et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 22 (2004) 520-527
66. Revaz V., Benyacoub J., Kast W.M., et al. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279 (2001) 354-360
67. De Bruijn M.L., Schuurhuis D.H., Vierboom M.P., et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res 58 (1998) 724-731
68. Freyschmidt E.J., Alonso A., Hartmann G., et al. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol. Antivir Ther 9 (2004) 479-489
69. Navabi H., Jasani B., Adams M., et al. Generation of in vitro autologous human cytotoxic T-cell response to E7 and HER-2/neu oncogene products using ex-vivo peptide loaded dendritic cells. Adv Exp Med Biol 417 (1997) 583-589
70. Kaufmann A.M., Nieland J., Schinz M., et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 92 (2001) 285-293
71. + lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J Virol 73 (1999) 5402-5410
72. Ferrara A., Nonn M., Sehr P., et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129 (2003) 521-530
73. Santin A.D., Bellone S., Gokden M., et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346 (2002) 1752-1753